iRhythm completes VitalConnect acquisition for $237.5 million cash, issues up to 423,334 shares
IRTC•iRhythm completed its acquisition of VitalConnect for $237.5 million in cash, up to 423,334 shares and $10 million in pre-close working-capital funding. The transaction is expected to lift revenue growth beginning in 2027 while maintaining a 15% adjusted EBITDA margin target for that year.
1. Acquisition completed
iRhythm completed its acquisition of VitalConnect, adding wearable biosensors, mobile cardiac telemetry and multi-vitals monitoring across ambulatory and inpatient settings. Consideration included $237.5 million in cash, up to 423,334 shares at closing and $10 million of working-capital funding before closing.
2. 2027 outlook
The transaction is expected to expand iRhythm’s addressable market into hospital-to-home care, using its health system relationships and integrated clinical services. It is expected to lift revenue growth beginning in 2027 while maintaining a 15% adjusted EBITDA margin target for 2027. iRhythm plans to provide updated 2026 guidance, including VitalConnect, on its third-quarter earnings call on Nov. 5, 2026.
